The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.

Risk warning:

Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.

Today's key assessments and concerns

Truist Securities: Maintaining a "buy" rating on AbCellera Biologics ( AbCellera Biologics, Inc.(ABCL.US) ), while raising the price target from $12 to $30.

Stifel: Maintaining a "buy" rating on Proficient Auto Logistics ( Proficient Auto Logistics, Inc.(PAL.US) ), while raising the price target from $9 to $12.

Morgan Stanley: Maintaining an "overweight" rating for Silence Therapeutics ( Silence Therapeutics PLC Sponsored ADR(SLN.US) ), while raising the price target from $25 to $32.

Craig-Hallum: Initial rating for Alterity Therapeutics ( Alteriry Therapeutics Ltd Sponsored ADR(ATHE.US) ) at "Buy", with a target price of $12.

HC Wainwright & Co.: Maintaining a "buy" rating on Nkarta Nkarta(NKTX.US) ) stock, while lowering the price target from $16 to $14.

The symbol	Classification	Target price	Current price	Percentage of potential increase/decrease	(Classification) Agency
AbCellera Biologics, Inc.(ABCL.US)	to lift	$30.0	$9.76	207.38%	Truist Securities
Proficient Auto Logistics, Inc.(PAL.US)	to lift	$12.0	$5.1	135.29%	Stifel
Silence Therapeutics PLC Sponsored ADR(SLN.US)	to lift	$32.0	$14.72	117.39%	Morgan Stanley
Jade Biosciences, Inc.(JBIO.US)	to lift	$47.0	$22.35	110.29%	Wedbush
Riot Platforms(RIOT.US)	to lift	$40.0	$20.24	97.63%	HC Wainwright & Co.
Alteriry Therapeutics Ltd Sponsored ADR(ATHE.US)	Initial classification	$12.0	$4.7	155.32%	Craig-Hallum
Nkarta(NKTX.US)	cut	$14.0	$2.33	500.86%	HC Wainwright & Co.
Metagenomi Therapeutics, Inc.(MGX.US)	cut	$7.0	$1.21	478.51%	Wells Fargo
Olema Pharmaceuticals, Inc.(OLMA.US)	cut	$59.0	$10.43	465.68%	Citigroup
Rocket Pharmaceuticals, Inc.(RCKT.US)	cut	$15.0	$3.5	328.57%	Wedbush

comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)

Lifting

Citigroup: Maintaining a "buy" rating on DraftKings ( DraftKings(DKNG.US) ), while raising the price target from $30 to $32.

UBS: Maintaining a "neutral" rating on eBay eBay Inc.(EBAY.US) ) stock, while raising its price target from $107 to $120.

TD Cowen: Maintaining a "Hold" rating on Intuit Intuit Inc.(INTU.US) ) stock, while raising the price target from $304 to $328.

Citigroup: Maintaining a "buy" rating on MongoDB MongoDB, Inc. Class A(MDB.US) ) stock, while raising the price target from $455 to $545.

Susquehanna: Maintaining a "positive" rating on Occidental Petroleum Occidental Petroleum Corporation(OXY.US) ) stock, while raising the price target from $67 to $70.

Bernstein: Maintaining its "outperform" rating for Taiwan Semiconductor Manufacturing Taiwan Semiconductor Manufacturing Co., Ltd. Sponsored ADR(TSM.US) , while raising its price target from $430 to $554.

First Coverage

Craig-Hallum: Initial rating for Alterity Therapeutics ( Alteriry Therapeutics Ltd Sponsored ADR(ATHE.US) ) at "Buy", with a target price of $12.

Compass Point: Initial rating for Sonida Senior Living ( Sonida Senior Living, Inc.(SNDA.US) ) at "Buy", with a target price of $65.

JP Morgan: Initial rating for Take-Two Take-Two Interactive Software, Inc.(TTWO.US) ) at "overweight", with a price target of $310.

reduction

Evercore ISI Group: Maintaining its "Outperform Market" rating for Caterpillar Caterpillar Inc.(CAT.US) stock, while lowering its price target from $1103 to $1045.

BTIG: Maintaining a "buy" rating on Tactile Systems Tech ( Tactile Systems Technology(TCMD.US) ), while lowering the price target from $40 to $39.

Wedbush: Maintaining a "neutral" rating on Vera Therapeutics ( Vera Therapeutics, Inc. Class A(VERA.US) ), while lowering the price target from $43 to $34.

Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.